Teikoku's Teikoku Pharma USA subsidiary granted Eisai exclusive rights to develop and commercialize Teikoku's transdermal formulation of donepezil for Alzheimer's disease outside of Japan

Teikoku Seiyaku Co. Ltd.

Japan / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Eisai Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced